Sharing Nath's reply to my question:
Question:
"Dr. Nath, last week you recommended the need for a platform trial where multiple drugs can be studied simultaneously as a next step. Is any funding currently in place to pursue this aspiration? If not, how can NINDS encourage and solicit grant applications on this proposed plan to help make this a reality? What are the next steps needed to accomplish this goal?"
From Nath:
“Platform trials is the way to go. A number of diseases are already looking into it. One of the diseases I study is ALS. There is an ongoing platform study in ALS. One can learn from that experience. So, Merit Cudkowicz at Harvard is the PI on that. It’s a multi-centered study. I think for platform studies you need large sample sizes, so you’re going to need multiple sites to enroll patients.
They are very expensive. Pharmaceutical companies really fund these things. Federal agencies don’t have that a kind of bandwidth. Most of the funding for clinical trials really come from pharmaceutical companies because they have the deep pockets to do these things, their budget is 10x that of NIH or more. I think what you need, is probably some kind of advisory committee that can go and design these things, try to raise funds from pharmaceutical companies to conduct these studies and learn from the ALS platform study. That is what I would suggest.”
https://twitter.com/i/web/status/1787575166605672822